Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial

[cafead]

via Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for further reductions in longer trials.

article source